Distinct expression pattern and prognostic values of pituitary tumor transforming gene family genes in non-small cell lung cancer

SHAOLONG YANG1*, XIAODI WANG2*, JINGXING LIU3*, BISHA DING4, KAIRI SHI5, JING CHEN6 and WEIYANG LOU4

1Department of Pathology, Zhengzhou Railway Vocational and Technical College, Zhengzhou, Henan 451460; 2Department of Emergency Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000; 3Department of Intensive Care Unit, Changxing People's Hospital of Zhejiang, Huzhou, Zhejiang 313100; 4Department of Surgery, Program of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang 310003; 5Department of Orthopedics and Traumatology, Traditional Chinese Medicine Hospital of Cixi, Ningbo, Zhejiang 315300; 6Department of Oncology, First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China

Received December 12, 2018; Accepted July 5, 2019

DOI: 10.3892/ol.2019.10844

Abstract. Members of the pituitary tumor transforming gene (PTTG) family, including PTTG1, PTTG2 and PTTG3P, exhibit pivotal roles in the onset and progression of certain types of human cancer. However, to the best of our knowledge, a systematic study regarding the expression pattern and the prognostic values of PTTG family genes in non-small cell lung cancer (NSCLC) remains to be performed. The expression levels of PTTG family genes in NSCLC were successively determined using the Gene Expression Profiling Interactive Analysis, UALCAN and Oncomine databases. Subsequently, the Kaplan-Meier plotter database was used to assess the prognostic value of the PTTG family genes in patients with NSCLC, and to determine the associations between PTTG expression levels and the prognosis of patients based on different clinicopathological features, including cancer stage, grade, chemotherapy, radiotherapy, lymph node status, smoking history, and sex. PTTG1 was identified to be significantly upregulated in NSCLC in all three databases, whereas PTTG2 and PTTG3P were significantly upregulated in NSCLC in only the UALCAN database. Patients with NSCLC with higher expression levels of the three PTTG genes demonstrated shorter overall survival times. In summary, the results of the present study suggested that increased expression of PTTG family genes may serve as promising prognostic biomarkers for patients with NSCLC.

Introduction

Lung cancer is the leading cause of cancer-associated mortality worldwide in men and women, and its prognosis remains dismal with a five-year survival rate of <15% (1). Non-small cell lung cancer (NSCLC), including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), accounts for ~75-80% of all lung cancer cases (2). In addition, although there are several treatment methods for patients with early-stage NSCLC, including surgery, chemotheraphy, radiotherapy and molecular targeted therapy, the number of NSCLC cases is still increasing. In addition, treatment options for patients with advanced disease are limited (3), and almost 80% of patients with NSCLC are first diagnosed at an advanced stage (4). Therefore, there is an

*Contributed equally

Abbreviations: NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PTTG, pituitary tumor transforming gene; GEPIA, Gene Expression Profiling Interactive Analysis; TCGA, The Cancer Genome Atlas; FC, fold-change; OS, overall survival; HR, hazard ratio; CI, confidence interval

Key words: pituitary tumor transforming gene, non-small cell lung cancer, Kaplan-Meier plotter, prognosis, in silico analysis, Oncomine, UALCAN, gene expression profiling interactive analysis
urgent requirement to conduct further investigations to study the mechanisms of the onset and progression of NSCLC, as well as to identify potential prognostic biomarkers. The development of prognostic biomarkers may improve the therapeutic choice for patients with NSCLC, and ultimately improve their prognosis.

The pituitary tumor transforming gene (PTTG) family is a novel class of homologous genes, which consists of three genes: PTTG1, PTTG2 and PTTG3P (5). The expression of PTTG1 is significantly upregulated in numerous endocrine-associated tumors, including pituitary, thyroid, breast and ovarian tumors (6). The dysregulation of PTTG1 enhances tumor cell proliferation, invasion and metastasis, and suppresses apoptosis (7-9). A number of studies have demonstrated that PTTG1 is an oncogene, and is overexpressed in human lung cancer. For example, Li et al (10) have reported that PPTG1 promotes the migration and invasion of NSCLC. In addition, Li et al (11) have demonstrated that knockdown of PTTG1 suppresses growth and invasion of LUAD, PTTG2 and PTTG3P, which are homologous genes of PTTG1, have recently been identified (5). Although little is understood regarding their biological functions, PTTG2 and PTTG3P have been revealed to be closely associated with the development of human cancer types. For example, Guo et al (12) have demonstrated that PTTG2 expression is significantly upregulated in glioblastoma, and its overexpression promotes glioblastoma cell proliferation and invasion. Weng et al (13) have demonstrated that PTTG3P enhances the in vitro proliferation and invasion of gastric cancer, and is an indicator of poor prognosis. However, to date, systematic analyses have not been performed for the mRNA expression pattern and prognostic roles of the PTTG family in NSCLC.

The present study determined the mRNA expression pattern of PTTG family genes in NSCLC, including LUAD and LUSC, using the Gene Expression Profiling Interactive Analysis (GEPIA), UALCAN and Oncomine databases. Subsequently, the prognostic values of PTTG family genes in NSCLC were assessed using the Kaplan-Meier plotter database. The Kaplan-Meier plotter database was also used to analyze the associations of PTTG1, PTTG2 and PTTG3P expression with the prognosis of patients based on clinicopathological features, including subtype, clinical stage, pathological grade, chemotherapy, radiotherapy, lymph node status, smoking history and sex. The in silico analysis performed in the present study may assist with the development of effective therapeutic targets and contribute to the improvement of the prognosis of patients with NSCLC.

Materials and methods

GEPIA database (http://geopia.cancer-pku.cn/detail.php). The expression levels of PTTG family genes in patients with LUAD and LUSC were evaluated using the GEPIA database, which is a newly developed interactive web server for analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression projects (14). The results of differential expression analyses (PTTG1, PTTG2 and PTTG3P in LUAD/LUSC) are available on the website (GEPIA). Fold-change (FC)>2 and P<0.05 were set as the thresholds of gene upregulation.

UALCAN database (http://ualcan.path.uab.edu/index.html). The expression levels of PTTG family genes in patients with LUAD and LUSC were further analyzed using the UALCAN database. UALCAN is a user-friendly, interactive web resource for analyzing TCGA transcriptome data (15). The analytical results were presented on the webpage (UALCAN). P<0.05 was considered to indicate a statistically significant result.

Oncomine database (https://www.oncomine.org). Oncomine, which is a cancer microarray database and a web-based data-mining platform, was used to analyze the expression levels of PTTG family genes in LUAD and LUSC samples compared with normal lung samples using the differential expression analysis provided by the database (16,17). FC>1.5, P<0.05 and a gene rank in the top 10% were set as the thresholds for selecting the datasets.

Kaplan-Meier plotter database (http://kmplot.com/analysis). The prognostic value of the mRNA expression levels of PTTG family genes in patients with NSCLC was assessed using the online database Kaplan-Meier plotter, previously described (18-20). Kaplan-Meier plotter was established using gene expression data and the survival information of patients with cancer downloaded from the Gene Expression Omnibus database (21). In the present study, the associations between PTTG1, PTTG2 and PTTG3P expression levels and the overall survival (OS) of patients with NSCLC were evaluated. Briefly, the three genes were first put into the database to obtain Kaplan-Meier survival plots. According to the median expression level, the cases were generally classified into low- and high-expression groups. A log-rank P-value, hazard ratio (HR) and 95% confidence interval (CI) were automatically calculated and presented on the webpage (Kaplan-Meier plotter). A log-rank P<0.05 was considered to indicate a statistically significant difference.

Results

Expression levels of the PTTG family genes in patients with NSCLC. To investigate the mRNA expression levels of PTTG family genes in human NSCLC, three online databases, including GEPIA, UALCAN and Oncomine, were successively used. The GEPIA database was used to compare the mRNA expression levels of PTTG family genes in NSCLC samples with those in normal lung samples. PTTG1 expression was significantly upregulated in NSCLC subtypes LUAD and LUSC compared with normal lung samples (Fig. 1A). However, no significant differences were identified between PTTG2 or PTTG3P expression in cancer tissues and normal tissues (Fig. 1B and C). PTTG3P expression levels in LUAD, LUSC and corresponding normal controls were extremely low. Similar results of the expression levels of PTTG family genes in NSCLC were obtained using the UALCAN database (Fig. 1D-I). The UALCAN database demonstrated that the expression levels of PTTG2 and PTTG3P were low (transcripts per million <1), which may lead to inaccurate statistical differences of PTTG2 and PTTG3P.

Oncomine analysis was used to further evaluate the mRNA expression of PTTG family genes in NSCLC. Similar to the previous results, PTTG1 expression was significantly
Figure 1. Expression of PTTG family in patients with non-small cell lung cancer from the GEPIA and UALCAN databases. (A-C) Expression of (A) PTTG1, (B) PTTG2 and (C) PTTG3P in patients with LUAD and LUSC in the GEPIA database. (D-F) Expression of (D) PTTG1, (E) PTTG2 and (F) PTTG3P in patients with LUAD in the UALCAN database. (G-I) Expression of (G) PTTG1, (H) PTTG2 and (I) PTTG3P in patients with LUSC in the UALCAN database. PTTG, pituitary tumor transforming gene; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TCGA, The Cancer Genome Atlas.
increased in both LUAD (Fig. 2) and LUSC (Fig. 3) compared with normal lung tissues. No significant differences were identified in the PTTG2 and PTTG3P expression levels between NSCLC and normal samples. The detailed information of the datasets with statistical significance information is presented in Table I. These data suggested that PTTG1 may be upregulated in NSCLC compared with normal lungs, whereas PTTG2 and PTTG3P are not dysregulated in NSCLC.

Prognostic values of PTTG family gene mRNA expression levels in patients with NSCLC. Kaplan-Meier plotter database was used to assess the effects of the mRNA expression levels of PTTG family genes on the survival of patients with NSCLC. The prognostic value of PTTG1 in all patients with NSCLC, patients with LUAD and patients with LUSC is presented in Fig. 4. Patients with NSCLC with high expression of PTTG1 exhibited significantly shorter OS time compared with patients with a low expression of PTTG1 (HR, 1.66; 95% CI, 1.46-1.89; log-rank P=5.7x10^{-15}; Fig. 4A). High expression of PTTG1 in patients with LUAD indicated a poor prognosis (HR, 2.36; 95% CI, 1.85-3.02; log-rank P=1.9x10^{-12}; Fig. 4B). However, in patients with LUSC, high PTTG1 expression was not associated with OS (Fig. 4C).

The associations between PTTG2 mRNA expression levels and the overall survival of all patients with NSCLC, patients with LUAD and patients with LUSC were also analyzed. High PTTG2 expression levels were only significantly associated
with a worse prognosis for all patients with NSCLC (HR, 1.21; 95% CI, 1.07-1.37; log-rank P=2.9x10^{-2}; Fig. 5A). For patients with LUAD (HR, 1.16; 95% CI, 0.92-1.46; log-rank P=2.0x10^{-1}) and patients with LUSC (HR, 1.06; 95% CI, 0.83-1.33; log-rank P=7.0x10^{-2}), PTTG2 expression was not significantly associated with the prognosis of patients (Fig. 5B and C).

The associations between PTTG3P mRNA expression level and survival for all patients with NSCLC, patients with LUAD and patients with LUSC were evaluated. As presented in Fig. 6A and B, high expression of PTTG3P was significantly associated with unfavorable OS for all patients with NSCLC (HR, 1.57; 95% CI, 1.38-1.78; log-rank P=2.9x10^{-15}) and
patients with LUAD (HR, 1.81; 95% CI, 1.43-2.30; log-rank P=7.1x10^{-7}). However, for patients with LUSC, PTTG3P was not significantly associated with OS (HR, 1.19; 95% CI, 0.94-1.50; log-rank P=1.6x10^{-1}; Fig. 6C). Taken together, these results indicated that the three PTTG family genes may be promising biomarkers that predict a poor prognosis in all patients with NSCLC. Additionally, PTTG1 and PTTG3P may also be two prospective prognostic biomarkers for patients with LUAD.

Associations between the prognostic values of PTTG family mRNA expression and clinical stage.

The associations between the prognostic values of the PTTG family mRNA expression levels and the clinical stage of patients with NSCLC were examined. Patients with clinical stage I NSCLC with high expression of PTTG1 (HR, 3.13; 95% CI, 2.32-4.21; log-rank P=3.2x10^{-15}; Fig. 7A), PTTG2 (HR, 1.43; 95% CI, 1.09-1.87; log-rank P=4.7x10^{-5}; Fig. 7B) and PTTG3P (HR, 2.73; 95% CI, 2.04-3.65; log-rank P=2.3x10^{-12}; Fig. 7C) exhibited worse OS compared with patients with low PTTG1 expression. High expression of PTTG2 indicated a poor prognosis in patients with clinical stage II NSCLC compared with low PTTG2 expression (HR, 1.61; 95% CI, 1.12-2.33; log-rank P=3.6x10^{-1}; Fig. 7I) expression levels exhibited no significant associations with prognosis. These results suggested that PTTG family genes may be effective prognostic biomarkers for patients with clinical stage I NSCLC.

Associations between the prognostic values of PTTG family mRNA expression and chemotherapy or radiotherapy.

Chemotherapy and radiotherapy are two major therapeutic strategies for treating different cancer types, including NSCLC, particularly for patients with advanced stage disease. The present study further investigated the associations between the prognostic roles of the mRNA expression levels of PTTG family genes and chemotherapy and radiotherapy in NSCLC. High expression levels of PTTG1 (HR, 1.58; 95% CI, 1.13-2.22; log-rank P=7.0x10^{-3}) and PTTG3P (HR, 1.45; 95% CI, 1.03-2.03; log-rank P=3.0x10^{-2}) were significantly associated with OS of patients with NSCLC without chemotherapy (Table II). However, none of the PTTG family gene expression levels were significantly associated with OS of patients with or without radiotherapy (Table III).

Associations between the prognostic values of PTTG family mRNA expression levels and other clinicopathological features.

The associations of individual PTTG family genes with other clinicopathological features, including pathological grade (Fig. 8), lymph node status (Table IV), smoking status (Table V) and sex (Table VI), were determined. Fig. 8 presents the prognostic values of PTTG family genes in NSCLC based on various pathological grades; none of the genes demonstrated a significant association with OS of patients with grade I, II
or III NSCLC, which may have occurred partially due to the relatively limited sample size. The data presented in Table IV demonstrated the associations between the prognostic values of PTTG family mRNA expression levels and lymph node status of patients with NSCLC. A high expression of PTTG1 (HR, 1.39; 95% CI, 1.12-1.71; log-rank P=2.3x10^{-3}) was significantly

<table>
<thead>
<tr>
<th>PTTG family member</th>
<th>Affymetrix ID</th>
<th>Chemotherapy</th>
<th>Low expression (N)</th>
<th>High expression (N)</th>
<th>HR</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTTG1</td>
<td>203554_x_at</td>
<td>No</td>
<td>155</td>
<td>155</td>
<td>1.58</td>
<td>1.13-2.22</td>
<td>7.0x10^{-3}a</td>
</tr>
<tr>
<td></td>
<td>203554_x_at</td>
<td>Yes</td>
<td>88</td>
<td>88</td>
<td>0.95</td>
<td>0.63-1.45</td>
<td>8.3x10^{-1}</td>
</tr>
<tr>
<td>PTTG2</td>
<td>214557_at</td>
<td>No</td>
<td>158</td>
<td>152</td>
<td>1.16</td>
<td>0.83-1.63</td>
<td>3.7x10^{-1}</td>
</tr>
<tr>
<td></td>
<td>214557_at</td>
<td>Yes</td>
<td>88</td>
<td>88</td>
<td>0.93</td>
<td>0.62-1.4</td>
<td>7.3x10^{-1}</td>
</tr>
<tr>
<td>PTTG3P</td>
<td>208511_at</td>
<td>No</td>
<td>156</td>
<td>154</td>
<td>1.45</td>
<td>1.03-2.03</td>
<td>3.0x10^{-2}a</td>
</tr>
<tr>
<td></td>
<td>208511_at</td>
<td>Yes</td>
<td>89</td>
<td>87</td>
<td>0.81</td>
<td>0.54-1.22</td>
<td>3.1x10^{-1}</td>
</tr>
</tbody>
</table>

aP<0.05. PTTG, pituitary tumor transforming gene.

Figure 4. Prognostic values of PTTG1 mRNA expression in all patients with NSCLC, patients with LUAD and patients with LUSC. (A-C) The prognostic value of PTTG1 mRNA expression in (A) all patients with NSCLC, (B) patients with LUAD and (C) patients with LUSC. PTTG, pituitary tumor transforming gene; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.
associated with poor OS for patients with NSCLC without invasive and/or metastatic lymph nodes (lymph node, 0). However, PTTG2 and PTTG3P were not associated with NSCLC lymph node status. Table V presents the associations of the PTTG family with the smoking history of patients with NSCLC.

Table III. Correlation of PTTG family with radiotherapy of patients with non-small cell lung cancer.

<table>
<thead>
<tr>
<th>PTTG family member</th>
<th>Affymetrix ID</th>
<th>Radiotherapy</th>
<th>Low expression (N)</th>
<th>High expression (N)</th>
<th>HR</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTTG1</td>
<td>203554_x_at</td>
<td>No</td>
<td>137</td>
<td>134</td>
<td>1.22</td>
<td>0.86-1.75</td>
<td>2.6x10⁻¹</td>
</tr>
<tr>
<td></td>
<td>203554_x_at</td>
<td>Yes</td>
<td>35</td>
<td>35</td>
<td>0.95</td>
<td>0.55-1.63</td>
<td>8.4x10⁻¹</td>
</tr>
<tr>
<td>PTTG2</td>
<td>214557_at</td>
<td>No</td>
<td>136</td>
<td>135</td>
<td>1.04</td>
<td>0.73-1.49</td>
<td>8.2x10⁻¹</td>
</tr>
<tr>
<td></td>
<td>214557_at</td>
<td>Yes</td>
<td>36</td>
<td>34</td>
<td>0.87</td>
<td>0.51-1.49</td>
<td>6.2x10⁻¹</td>
</tr>
<tr>
<td>PTTG3P</td>
<td>208511_at</td>
<td>No</td>
<td>136</td>
<td>135</td>
<td>1.11</td>
<td>0.77-1.58</td>
<td>5.8x10⁻¹</td>
</tr>
<tr>
<td></td>
<td>208511_at</td>
<td>Yes</td>
<td>35</td>
<td>35</td>
<td>1.15</td>
<td>0.68-1.96</td>
<td>6.0x10⁻¹</td>
</tr>
</tbody>
</table>

PTTG, pituitary tumor transforming gene.

Figure 5. Prognostic values of PTTG2 mRNA expression in all patients with NSCLC, patients with LUAD and patients with LUSC. (A-C) The prognostic value of PTTG2 mRNA expression in (A) all patients with NSCLC, (B) patients with LUAD and (C) patients with LUSC. PTTG, pituitary tumor transforming gene; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.
Table IV. Correlation of PTTG family with lymph node status of patients with non-small cell lung cancer.

<table>
<thead>
<tr>
<th>PTTG family member</th>
<th>Affymetrix ID</th>
<th>Lymph node status</th>
<th>Low expression (N)</th>
<th>High expression (N)</th>
<th>HR</th>
<th>95% CI</th>
<th>Log-rank P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTTG1</td>
<td>203554_x_at</td>
<td>0</td>
<td>390</td>
<td>391</td>
<td>1.39</td>
<td>1.12-1.71</td>
<td>2.3x10^{-3}</td>
</tr>
<tr>
<td></td>
<td>214775_at</td>
<td>1</td>
<td>126</td>
<td>126</td>
<td>1.21</td>
<td>0.89-1.66</td>
<td>2.3x10^{-4}</td>
</tr>
<tr>
<td></td>
<td>208511_at</td>
<td>2</td>
<td>56</td>
<td>55</td>
<td>1.01</td>
<td>0.67-1.51</td>
<td>9.7x10^{-4}</td>
</tr>
<tr>
<td>PTTG2</td>
<td>203554_x_at</td>
<td>0</td>
<td>391</td>
<td>390</td>
<td>1.06</td>
<td>0.86-1.31</td>
<td>5.7x10^{-4}</td>
</tr>
<tr>
<td></td>
<td>214775_at</td>
<td>1</td>
<td>129</td>
<td>123</td>
<td>1.22</td>
<td>0.89-1.67</td>
<td>2.1x10^{-4}</td>
</tr>
<tr>
<td></td>
<td>208511_at</td>
<td>2</td>
<td>56</td>
<td>55</td>
<td>1.23</td>
<td>0.82-1.84</td>
<td>3.2x10^{-4}</td>
</tr>
<tr>
<td>PTTG3P</td>
<td>203554_x_at</td>
<td>0</td>
<td>391</td>
<td>390</td>
<td>1.12</td>
<td>0.9-1.38</td>
<td>3.1x10^{-4}</td>
</tr>
<tr>
<td></td>
<td>214775_at</td>
<td>1</td>
<td>128</td>
<td>124</td>
<td>1.24</td>
<td>0.91-1.69</td>
<td>1.8x10^{-4}</td>
</tr>
<tr>
<td></td>
<td>208511_at</td>
<td>2</td>
<td>56</td>
<td>55</td>
<td>1.32</td>
<td>0.88-1.97</td>
<td>1.8x10^{-4}</td>
</tr>
</tbody>
</table>

\(^{a}P<0.05.\) PTTG, pituitary tumor transforming gene.

Figure 6. Prognostic values of PTTG3P mRNA expression in all patients with NSCLC, patients with LUAD and patients with LUSC. (A-C) The prognostic value of PTTG3P mRNA expression in (A) all patients with NSCLC, (B) patients with LUAD and (C) patients with LUSC. PTTG, pituitary tumor transforming gene; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

95% CI, 1.63-5.62; log-rank P=2.2x10^{-4}) or smoked (HR, 1.32; 95% CI, 1.07-1.62; log-rank P=8.9x10^{-7}). Patients with NSCLC with a high expression of PTTG2 who had smoked (HR, 1.47; 95% CI, 1.19-1.81; log-rank P=2.8x10^{-4}) and never-smoked (HR, 2.10; 95% CI, 1.18-3.75; log-rank P=1.0x10^{-5}) exhibited a shorter OS time compared with patients with NSCLC with low
Figure 7. Prognostic values of the mRNA expression PTTG family in NSCLC patients based on different clinical stages. (A-C) The prognostic value of (A) PTTG1, (B) PTTG2 and (C) PTTG3P mRNA expression in patients with clinical stage I NSCLC. (D-F) The prognostic value of (D) PTTG1, (E) PTTG2 and (F) PTTG3P mRNA expression in patients with clinical stage II NSCLC. (G-I) The prognostic value of (G) PTTG1, (H) PTTG2 and (I) PTTG3P mRNA expression in patients with clinical stage III NSCLC. PTTG, pituitary tumor transforming gene; NSCLC, non-small cell lung cancer.
Figure 8. The prognostic values of the mRNA expression PTTG family in NSCLC patients based on different pathological grades. (A-C) The prognostic value of (A) PTTG1, (B) PTTG2 and (C) PTTG3P mRNA expression in patients with pathological grade I NSCLC. (D-F) The prognostic value of (D) PTTG1, (E) PTTG2 and (F) PTTG3P mRNA expression in patients with pathological grade II NSCLC. (G-I) The prognostic value of (G) PTTG1, (H) PTTG2 and (I) PTTG3P mRNA expression in patients with pathological grade III NSCLC. PTTG, pituitary tumor transforming gene; NSCLC, non-small cell lung cancer.
expression of PTTG2. Additionally, high expression of PTTG3P was also significantly associated with the OS of those who had never-smoked (HR, 3.11; 95% CI, 1.70-5.71; log-rank P=1.1x10^{-4}) and smoked (HR, 1.41; 95% CI, 1.15-1.74; log-rank P=1.1x10^{-3}). High expression of PTTG1, PTTG2 and PTTG3P was significantly associated with OS of both female and male patients with NSCLC (PTTG1-female: HR, 1.87; 95% CI, 1.47-2.38; log-rank P=1.7x10^{-7}; PTTG1-male: HR, 1.52; 95% CI, 1.31-1.79; log-rank P=1.2x10^{-7}).

**Discussion**

Lung cancer is the leading cause of cancer-associated mortality worldwide, which is associated with significant health and financial burdens (1). As the most common type or lung cancer, rapid improvements in the diagnosis, treatment and prognosis of NSCLC is important. The PTTG family, which comprises PTTG1, PTTG2 and PTTG3P, is a newly identified gene class. Among the three homologous genes, PTTG1 has been the most extensively studied and has been identified to be closely associated with the onset and progression of multiple human cancer types, including pituitary tumor (22), malignant glioma (7), thyroid (23), breast (24), ovarian (25), bladder (8), prostate (9) and lung cancer (26-30).

Honda et al (30) have demonstrated that PTTG1 is significantly upregulated in NSCLC and its overexpression serves a role in the genesis and progression of NSCLC. However, to the best of our knowledge, no previous study has investigated their expression and roles in NSCLC. Therefore, the present study systematically investigated the expression and prognostic roles of the PTTG family genes in NSCLC.

A comprehensive analysis of the mRNA expression of the PTTG family genes in NSCLC was performed in the present study using the GEPIA, UALCAN and Oncomine databases. The results demonstrated that PTTG1 was significantly upregulated in cancer tissue compared with normal tissue, which was in accordance with the results of previous studies on other types of cancer (7-9). By contrast, for PTTG2 and PTTG3P expression, the data from the three databases were inconsistent. The results from the GEPIA and Oncomine database analysis suggested that there were no significant differences in PTTG2 and PTTG3P expression between NSCLC and normal lung tissues. However, the results from the UALCAN database indicated an upregulation of PTTG2 and PTTG3P in NSCLC compared with normal tissue. Therefore, further studies on the expression of these genes in NSCLC are required to confirm these results.
The Kaplan Meier-plotter database was used to perform a broad assessment of the prognostic roles of the PTTG family genes in patients with NSCLC. The results demonstrated that patients with NSCLC (1,924 samples) with high PTTG1, PTTG2 and PTTG3P expression exhibited a shorter OS time compared with healthy controls. In different subtypes of patients with NSCLC, PTTG1 and PTTG3P may serve as promising prognostic biomarkers, as their mRNA expression levels were significantly associated with the prognosis of patients with LUAD. However, for patients with LUAD and LUSC, PTTG2 was not significantly associated with prognosis. Only 720 and 524 clinical samples were included in the analysis of the prognostic roles of PTTG family genes in patients with LUAD and LUSC, respectively; the relatively small sample counts may have influenced the results.

The present study further determined the associations of the prognostic values of the mRNA expression of PTTG family genes with clinicopathological features, including clinical stage, pathological grade, lymph node metastasis, smoking history and sex. The associations between the levels of PTTG family mRNA expression and chemotherapy or radiotherapy were also assessed. The findings demonstrated that a high expression of PTTG family genes indicated a poor prognosis in patients with clinical stage 1 disease, patients who had smoked, patients who had never-smoked. No differences were observed in terms of the sex of the patients in the prognosis of patients with NSCLC with high expression of PTTG family genes. High expression levels of PTTG1 and PTTG3P were associated with short survival time of patients with NSCLC who had not received chemotherapy. PTTG family genes demonstrated no significant association with radiotherapy, pathological grade and lymph node status, partially due to the relatively limited sample size. These results may inform the selection of therapeutic choices for NSCLC patients with various PTTG family gene expression levels. Future studies with a larger sample size are required to further reveal the associations of the expression levels of PTTG family genes with these clinicopathological features in patients with NSCLC. Of note, in addition to LUAD and LUSC subtypes, NSCLC also has other subtypes, such as lung adenosquamous carcinoma and large cell lung cancer. Therefore, although PTTG family exhibited unfavorable prognostic values in all NSCLC patients, they may have various prognostic values in LUAD or LUSC.

In conclusion, the results of the present study suggest that PTTG family genes, particularly PTTG1, are significantly overexpressed in LUAD and LUSC. In addition, increased expression of PTTG family genes may serve as promising prognostic biomarkers for patients with NSCLC.

Acknowledgements

Not applicable.

Funding

This study was supported by the 2017 Science and Technology Innovation Team Project of Zhengzhou Railway Vocational and Technical College (grant no. 17060001).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

WL and JC conceived and designed the study. SY, XW and JL wrote the manuscript. SY, XW and JL performed gene expression analysis, survival analysis and prepared figures and tables. BD and KS interpreted the results. BD, KS and WL revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.